Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kakkonto is a traditional Japanese Kampo medicine (Kudzu Decoction) composed of seven herbal ingredients: Puerariae Radix, Ephedrae Herba, Cinnamomi Cortex, Paeoniae Radix, Glycyrrhizae Radix, Zingiberis Rhizoma, and Ziziphi Fructus. It is traditionally used in Japan for the treatment of the early stages of acute febrile diseases, such as the common cold and influenza, as well as inflammatory conditions like stiff neck and shoulders. Its mechanism of action involves anti-inflammatory, antipyretic, and immunomodulatory effects, likely mediated by components such as ephedrine (from Ephedra) and glycyrrhizin (from Licorice). Recently, it has been investigated in clinical trials (e.g., IMJEDI study-R1) as an add-on therapy for mild-to-moderate COVID-19 to alleviate symptoms and prevent progression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kakkonto.